494799-17-6|3-Cyclohexyl-1H-indole-6-carboxylic acid| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 494799-17-6 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 494799-17-6 ]

CAS No. :	494799-17-6
Formula :	C₁₅H₁₇NO₂
M.W :	243.30
SMILES Code :	O=C(C1=CC2=C(C=C1)C(C3CCCCC3)=CN2)O
MDL No. :	MFCD09833286
InChI Key :	OZJSQVKDKOOQIT-UHFFFAOYSA-N
Pubchem ID :	11241989

Safety of [ 494799-17-6 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H317
Precautionary Statements:	P280

Computational Chemistry of [ 494799-17-6 ] Show Less

Physicochemical Properties

Num. heavy atoms	18
Num. arom. heavy atoms	9
Fraction Csp3	0.4
Num. rotatable bonds	2
Num. H-bond acceptors	2.0
Num. H-bond donors	2.0
Molar Refractivity	72.14
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	53.09 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.15
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	4.11
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	3.91
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	2.74
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	3.58
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	3.3

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-4.18
Solubility	0.0162 mg/ml ; 0.0000667 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-4.93
Solubility	0.00285 mg/ml ; 0.0000117 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-4.1
Solubility	0.0193 mg/ml ; 0.0000794 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	Yes
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	Yes
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	Yes
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-4.87 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.56

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<2.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.0

Application In Synthesis of [ 494799-17-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 494799-17-6 ]

[ 494799-17-6 ] Synthesis Path-Downstream 1~35

1
[ 494799-16-5 ]
[ 494799-17-6 ]

Yield	Reaction Conditions	Operation in experiment
90%	With hydrogen;palladium hydroxide on carbon; In tetrahydrofuran; methanol; under 3102.97 Torr; for 14h;	Step 2; methy\\ 3-cvclohexyl-1H-indole-6-carboxylate; A solution (0.5 M) of 3-cyclohexenyl-1H-indole-6-carboxylic acid (from Step 1) in THF/M eOH (0.5 M, 1:1, v/v) was hydrogenated for 14 h over Pd(OH)2/C (0.1 eq., 20percent) at 60 psi. The catalyst was removed by filtration on a pad of celite.(TM). and the filtrate evaporated to dryness to afford 3-cyclohexyl-1 H-indoIe-6-carboxylic acid (90percent) as a white solid 1H NMR (300 MHz, DMSO-d6, 300 K) 6 1.20 -1.53 (m, SH), L70-L87 (m, 3H), 1.90-2.02 (m, 2H), 2.69-2.86 (m, 1H), 7.40 (s, 1H), 7.55-7.65 (rn, 2H), 8.0 (s, 1H), 11.40 (s, 1H); MS (ES+ m/z 244 (M+H)+. A solution of the foregoing compound in MeOH {0.4 M) was treated at 0 °C with thionylchloride (0.5 eq.) and refluxed for 24 h. Volatiles were removed under vacuum to afford the title compound (100percent) as a solid.
90%	With ammonium formate;palladium 10% on activated carbon; In ethanol; at 50℃; for 4h;	To a solution of 3-(1-cyclohexen-1-yl)-1 H-indole-6-carboxylic acid (Intermediate 60) (1 g, 4.1 mmol) in ethanol was added Pd/C 10percent (catalytic quantity) and ammonium formiate (2.6 g, 41 mmol). The mixture was stirred at 500C for 4 hours. A precipitate was formed, HCI 1 N was added until the precipitate was dissolved. The mixture was filtered on celite, the filtrate was evaporated. The residue was diluted with diethyl ether, washed with water. The organic phase was dried over Na2SO4, filtered and evaporated to give the title compound as beige solid (900 mg, 90percent). NMR1H NMR (300 MHz), , delta : 7.96 (s, 1 H), 7.57 (q, 2H), 7.28 (s, 1 H), 2.77 (m, 1 H), 1.96 (m, 1 H), 1.77 (m, 3H), 1.43 (m, 4H), 1.26 (m, 1 H).
87%	With hydrogen;palladium hydroxide on carbon; In tetrahydrofuran; methanol; at 20℃; under 2844.39 Torr; for 3h;	Step B.A mixture of 1-2 (14.0 g, 58 mmol) and 20percent Pd(OH)2/C (600 mg) in methanol (50 mL) and THF (50 mL) was shaken in a hydrogenation apparatus under 55 psi pressure at room temperature for 3 h. The catalyst was removed by filtration and washed with methanol. The filtrate was concentrated to dryness. The residue was triturated in hexane, then the beige solid was collected by filtration, washed with hexane and dried under vacuum to give 12.3 g (87percent) of the target product 1-3: m/z : 244 (M+H)+.

83%	With hydrogen;palladium 10% on activated carbon; In tetrahydrofuran; methanol; dichloromethane; under 2585.81 - 3102.97 Torr; for 15h;	Step 4. 3-Cyclohexyl-1H-indole-6-carboxylic acid (164)[0310] Compound 163 from Step 3 (75.5g) was split into two batches. Each batches were suspended in 600 mL solvent (1:1 MeOH:THF). Pd catalyst (10percent on carbon, Ig / batch) was added as a slurry in CH2Cl2 (5 mL) and the mixture was hydrogenated for 15hr at 50-60 psi. The catalyst was filtered off by means of Celite and the solvents were removed via vacuum distillation to a give compound 164 as a yellow solid. Yield 63g (83percent).
79%	With hydrogen;palladium 10% on activated carbon; In tetrahydrofuran; methanol; at 20℃; under 2844.39 Torr; for 18h;	3-Cyclohexyl-1H-indole-6-carboxylic acid; 3-Cyclohexenyl-1H-indole-6-carboxylic acid (38 g) was added to a Parr bottle, followed by methanol (100 mL) and THF (100 mL). The bottle was flushed with argon and 10percent palladium on carbon (1.2 g) was added. The flask was then evacuated and subsequently refilled with H2 to a pressure of 55 psi, and the resultant mixture was shaken for 18 hours at RT. The catalyst was then removed by filtration through celite. Concentration of the filtrate provided the desired product as a pale purple solid (30.6 g, 79percent). ESI-MS m/z 244 (MH+).
79%	With hydrogen;palladium 10% on activated carbon; In tetrahydrofuran; methanol; at 20℃; under 2844.39 Torr; for 18h;	3-Cyclohexyl-1H-indole-6-carboxylic acid.; 3-Cyclohexenyl-1H-indole-6-carboxylic acid (38 g) was added to a Parr bottle, followed by methanol (100 mL) and THF (100 mL). The bottle was flushed with argon and 10percent palladium on carbon (1.2 g) was added. The flask was then evacuated and subsequently refilled with H2 to a pressure of 55 psi, and the resultant mixture was shaken for 18 hours at RT. The catalyst was then removed by filtration through celite. Concentration of the filtrate provided the desired product as a pale purple solid (30.6 g, 79percent). ESI-MS m/z 244 (MH+).
79%	With hydrogen;palladium 10% on activated carbon; In tetrahydrofuran; methanol; at 20℃; under 2844.39 Torr; for 18h;	3-Cyclohexyl-1H-indole-6-carboxylic acid. 3-Cyclohexenyl-1H-indole-6-carboxylic acid (38 g) was added to a Parr bottle, followed by methanol (100 mL) and THF (100 mL). The bottle was flushed with argon and 10percent palladium on carbon (1.2 g) was added. The flask was then evacuated and subsequently refilled with H2 to a pressure of 55 psi, and the resultant mixture was shaken for 18 hours at RT. The catalyst was then removed by filtration through celite. Concentration of the filtrate provided the desired product as a pale purple solid (30.6 g, 79percent). ESI-MS m/z 244 (MH+).
79%	With hydrogen;palladium 10% on activated carbon; In tetrahydrofuran; methanol; under 2844.39 Torr; for 18h;Parr bottle;	3-cyclohexyl-1H-indole-6-carboxylic acid. Intermediate 3A (38 g) was added to a Parr bottle, followed by methanol (100 mL) and THF (100 mL). The bottle was flushed with argon and 10percent palladium on carbon (1.2 g) was added. The mixture was shaken under 55 psi of H2 for 18 hours. The catalyst was removed by filtration. Concentration of the filtrate provided the desired product as a pale purple solid (30.6 g, 79percent). ESI-MS m/z 244 (MH+).
79%	With hydrogen;palladium 10% on activated carbon; In tetrahydrofuran; methanol; at 20℃; under 2844.39 Torr; for 18h;	3-Cyclohexyl-1H-indole-6-carboxylic acid.; 3-Cyclohexenyl-1H-indole-6-carboxylic acid (38 g) was added to a Parr bottle, followed by methanol (100 mL) and THF (100 mL). The bottle was flushed with argon and 10percent palladium on carbon (1.2 g) was added. The flask was then evacuated and subsequently refilled with H2 to a pressure of 55 psi, and the resultant mixture was shaken for 18 hours at RT. The catalyst was then removed by filtration through celite. Concentration of the filtrate provided the desired product as a pale purple solid (30.6 g, 79percent). ESI-MS m/z 244 (MH+).
79%	With hydrogen;palladium 10% on activated carbon; In tetrahydrofuran; methanol; at 20℃; under 2844.39 Torr; for 18h;	Intermediate 17 3-Cyclohexyl-1H-indole-6-carboxylic acid. 3-Cyclohexenyl-1H-indole-6-carboxylic acid (38 g) was added to a Parr bottle, followed by methanol (100 mL) and THF (100 mL). The bottle was flushed with argon and 10percent palladium on carbon (1.2 g) was added. The flask was then evacuated and subsequently refilled with H2 to a pressure of 55 psi, and the resultant mixture was shaken for 18 hours at RT. The catalyst was then removed by filtration through celite. Concentration of the filtrate provided the desired product as a pale purple solid (30.6 g, 79percent). ESI-MS m/z 244 (MH+).
79%	With hydrogen;palladium 10% on activated carbon; In tetrahydrofuran; methanol; at 20℃; under 2844.39 Torr; for 18h;	3-Cyclohexenyl-1H-indole-6-carboxylic acid (38 g) was added to a Parr bottle, followed by methanol (100 mL) and THF (100 mL). The bottle was flushed with argon and 10percent palladium on carbon (1.2 g) was added. The flask was then evacuated and subsequently refilled with H2 to a pressure of 55 psi, and the resultant mixture was shaken for 18 hours at RT. The catalyst was then removed by filtration through celite. Concentration of the filtrate provided the desired product as a pale purple solid (30.6 g, 79percent). ESI-MS m/z 244 (MH+).
78%	With hydrogen;palladium(II) hydroxide/carbon; In tetrahydrofuran; methanol; under 2844.39 Torr; for 20h;	The unsaturated derivative from above was hydrogenated for 20 h under 55 psi hydrogen gas pressure over 20percent Pd (OH) 2/C (10.25 g) using 1: 1 THF-MEOH (2.5 L) as solvent. After filtration of the catalyst, volatiles were removed under reduced pressure and the residue was triturated with hexane. The beige solid was collected by filtration, washed with hexane and dried under vacuum (356.4 g, 78percent yield).
50%	With palladium 10% on activated carbon; ammonium formate; In ethanol; at 50℃; for 4h;	To a stirred solution of compound 34 (2 g, 8.29 mmol) in EtOH (20 mL) under argon atmosphere, 10percent Pd/C (200 mg) and ammonium formate (5.2 g, 82.9 mmol) was added. The reaction mass was stirred at 50 °C for 4 h. The progress of the reaction was monitored by TLC. After completion, the reaction mass cooled to RT, quenched with iN HC1 and ethyl acetate andfiltered through a pad of celite. The organic layer was separated, dried over anhydrous sodium sulfate and concentrated in vacuo to afford the crude. The crude compound was triturated with DCM to afford compound C19 (1 g, 50percent) as a light-brown solid. ?H-NMR (400 MHz, DMSOd 6): oe 12.42 (s, 1H), 11.13 (s, 1H), 7.98 (s, 1H), 7.62?7.57 (m, 2H), 7.30 (s, 1H), 2.80?2.76 (m, 1H), 1.99 ? 1.97 (m, 2H), 1.88 - 1.71 (m, 4H), 1.50 ? 1.38 (m, 4H), LCMS Observed (m/z):244.05 (M+1).

References: [1]Patent: WO2006/29912,2006,A1 .Location in patent: Page/Page column 21-22.
[2]Patent: WO2009/147121,2009,A1 .Location in patent: Page/Page column 65-66.
[3]Patent: WO2009/80836,2009,A2 .Location in patent: Page/Page column 56.
[4]Patent: WO2006/76529,2006,A1 .Location in patent: Page/Page column 135.
[5]Patent: US2007/78122,2007,A1 .Location in patent: Page/Page column 174.
[6]Patent: US2007/60565,2007,A1 .Location in patent: Page/Page column 70-71.
[7]Patent: US2007/275947,2007,A1 .Location in patent: Page/Page column 3; 32.
[8]Patent: US2006/46983,2006,A1 .Location in patent: Page/Page column 18; 38.
[9]Patent: US2008/188458,2008,A1 .Location in patent: Page/Page column 32-33.
[10]Patent: US2008/171015,2008,A1 .Location in patent: Page/Page column 23.
[11]Patent: US2008/226592,2008,A1 .Location in patent: Page/Page column 4; 36.
[12]Patent: WO2004/65367,2004,A1 .Location in patent: Page 110.
[13]Patent: WO2018/53157,2018,A1 .Location in patent: Page/Page column 162; 163.
[14]Journal of Medicinal Chemistry,2005,vol. 48,p. 1314 - 1317.
[15]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4987 - 4993.

2
[ 494799-17-6 ]
[ 74-88-4 ]
[ 494799-18-7 ]

Yield	Reaction Conditions	Operation in experiment
92.6%	With potassium carbonate; In N,N-dimethyl-formamide; at 20℃; for 4h;	To a stirred solution of compound C19 (0.5 g, 2.07 mmol) in DMF (6 mL), K2C03 (0.395 g, 2.85 mmol) and Mel (0.32 g, 2.26 mmol) were added. The resulting reaction mixture was stirred at RT for 4 h. The progress of the reaction was monitored by TLC. After completion,the reaction mixture was diluted with ice cold water (50 mL) and extracted with DCM (3 x 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford the crude compound 35 (0.49 g, 92.6percent) as a pale-yellow oil. The crude compound was used as such for the next step without further purification. TLC: 50percent EtOAc/ hexane (Rf: 0.6), ?H-NMR (400 MHz, CDC13): oe 8.17 (br.s, 1H), 8.12 (s, 1H), 7.79 (d,J= 8.4 Hz, 1H), 7.68 (d, J= 8.4 Hz, 1H), 7.13 (s, 1H), 3.90 (s, 3H), 2.86 ?2.84 (m, 1H), 2.12 ?2.06 (m, 2H), 1.86 ? 1.79 (m, 2H), 1.58 -1.43 (m, 4H), 1.38 ? 1.27 (m, 2H); LCMS Observed (m/z): 258 (M+1).
90%	With potassium carbonate; In DMF (N,N-dimethyl-formamide); at 20℃;	A 2 L flask equipped with a dropping funnel and mechanical stirrer was charged with crude <strong>[494799-17-6]3-cyclohexyl-6-indole carboxylic acid</strong> (99.4 g, 0.409 mole) and anhydrous DMF (665 mL) was added followed by anhydrous potassium carbonate (78.13 g, 0.565 mole). lodomethane (63.72 g, 0.449 mole) was added dropwise over 35 min with stirring to the slurry which was then stirred overnight at room temperature until complete disappearance of starting material (TLC). The resulting suspension was then poured into water (1350 mL) and acidified to pH 4 with 4N HCI (200 mL). The product was extracted into ether (3 x 1700 mL), washed with water and brine and dried (NA2SO4). VOLATILES were removed under reduced pressure and the residue was triturated with hexane (700 mL). The beige solid was filtered and dried under vacuum (94.3 g, 90 percent yield).

References: [1]Patent: WO2018/53157,2018,A1 .Location in patent: Page/Page column 163; 164.
[2]Patent: WO2004/65367,2004,A1 .Location in patent: Page 110 - 111.
[3]Journal of Medicinal Chemistry,2005,vol. 48,p. 1314 - 1317.
[4]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4987 - 4993.

3
[ 494799-17-6 ]
[ 494799-19-8 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4987 - 4993.
[2]Journal of Medicinal Chemistry,2005,vol. 48,p. 1314 - 1317.
[3]Patent: WO2018/53157,2018,A1 .
[4]Patent: US2008/188458,2008,A1 .
[5]Patent: US2008/171015,2008,A1 .
[6]Patent: US2008/226592,2008,A1 .

4
[ 494799-17-6 ]
[ 494799-14-3 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4987 - 4993.
[2]Journal of Medicinal Chemistry,2005,vol. 48,p. 1314 - 1317.

5
[ 494799-17-6 ]
3-cyclohexyl-1-methyl-2-phenyl-1H-indole-6-carboxylic acid methyl ester [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4987 - 4993.
[2]Journal of Medicinal Chemistry,2005,vol. 48,p. 1314 - 1317.

6
[ 494799-17-6 ]
3-cyclohexyl-1-methyl-2-phenyl-1H-indole-6-carboxylic acid [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4987 - 4993.
[2]Journal of Medicinal Chemistry,2005,vol. 48,p. 1314 - 1317.

7
[ 494799-17-6 ]
[ 494799-15-4 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4987 - 4993.
[2]Journal of Medicinal Chemistry,2005,vol. 48,p. 1314 - 1317.

8
[ 494799-17-6 ]
[ 494799-20-1 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4987 - 4993.

9
[ 494799-17-6 ]
[ 494799-21-2 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4987 - 4993.

10
[ 494799-17-6 ]
[ 494799-22-3 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4987 - 4993.

11
[ 494799-17-6 ]
3-cyclohexyl-2-furan-3-yl-1-methyl-1H-indole-6-carboxylic acid methyl ester [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4987 - 4993.

12
[ 494799-17-6 ]
3-cyclohexyl-2-furan-3-yl-1H-indole-6-carboxylic acid [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4987 - 4993.

13
[ 494799-17-6 ]
[ 494799-77-8 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4987 - 4993.

14
[ 1670-82-2 ]
[ 494799-17-6 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4987 - 4993.
[2]Patent: US2008/188458,2008,A1 .
[3]Patent: US2008/171015,2008,A1 .

15
[ 108-94-1 ]
CS₂ [ No CAS ]
[ 494799-17-6 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4987 - 4993.

16
[ 494799-17-6 ]
[ 735287-38-4 ]